Kronos Bio Stock News

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Kronos Bio, Inc. (NASDAQ:KRON) shares gapped down before the market opened on Tuesday . The stock had previously closed at $14.00, but opened at $13.70. Kronos Bio shares last traded at $14.66, with a volume of 1,131 shares trading hands. Several analysts recently commented on KRON shares. Zacks Investment Research raised Kronos Bio from a […] The post Kronos Bio (NASDAQ:KRON) Shares Gap Down to $14.00 appeared first on ETF Daily News .

Kronos Bio, Inc. (NASDAQ:KRON) VP Jorge Dimartino sold 16,402 shares of the firms stock in a transaction that occurred on Monday, December 13th. The stock was sold at an average price of $12.37, for a total value of $202,892.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through []

Oncorus (NASDAQ:ONCR) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 79.6% of Oncorus shares are held by institutional investors. Comparatively, 68.3% of []

Kronos Bio, Inc. (NASDAQ:KRON) CEO Norbert W. Bischofberger acquired 14,356 shares of the firms stock in a transaction dated Monday, December 6th. The stock was bought at an average cost of $12.09 per share, with a total value of $173,564.04. The transaction was disclosed in a document filed with the SEC, which is available at []

Related Stocks: KRON ,

Data in the second half of 2023 could potentially lead to accelerated approval If approved, entospletinib would be the first treatment for newly diagnosed patients with the NPM1 mutation who are fit for intensive induction

Kronos Bio, Inc. gapped up prior to trading on Wednesday. The stock had previously closed at $11.81, but opened at $12.35. Kronos Bio shares last traded at $11.87, with a

Kronos Bio, Inc. (NASDAQ:KRON) gapped up prior to trading on Wednesday . The stock had previously closed at $11.81, but opened at $12.35. Kronos Bio shares last traded at $11.87, with a volume of 71 shares changing hands. Several analysts recently issued reports on KRON shares. Cowen started coverage on Kronos Bio in a report [] The post Kronos Bio (NASDAQ:KRON) Shares Gap Up to $11.81 appeared first on ETF Daily News .

Kronos Bio, Inc. (NASDAQ:KRON) Director Backer Marianne De acquired 1,150 shares of the stock in a transaction dated Wednesday, December 1st. The shares were bought at an average price of $11.57 per share, for a total transaction of $13,305.50. The acquisition was disclosed in a document filed with the SEC, which is accessible through this []

Initial data demonstrate long plasma half-life and dose-dependent target inhibition

Shares of Kronos Bio, Inc. (NASDAQ:KRON) hit a new 52-week low during trading on Wednesday . The company traded as low as $12.85 and last traded at $12.85, with a volume of 435 shares trading hands. The stock had previously closed at $13.34. A number of equities analysts have recently issued reports on KRON shares. []

Kronos Bio Inc. (NASDAQ:KRON) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -1.80% to the previous days close as strong demand from buyers drove the stock to $13.10. Actively observing the price movement in the last trading, the stock closed the session at $13.34, falling within a range of $12.64 Is Kronos Bio Inc. (NASDAQ: KRON) A Suitable Stock For New Investors Today? Read More »

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:

SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th